| Jingjing Liu,Shuang Zhang,Lixia Ma,Chunjiao Wu,Changliang Yang,Xuerong Zuo,Ying Cheng. Efficacy analysis and multi-factor retrospective study of third-line chemotherapy in 82 Chinese patients with small cell lung cancer. Oncol Transl Med, 2015, 1: 26-31. |
| Efficacy analysis and multi-factor retrospective study of third-line chemotherapy in 82 Chinese patients with small cell lung cancer |
| Received:December 31, 2014 Revised:December 31, 2014 |
| View Full Text View/Add Comment Download reader |
| KeyWord:small cell lung cancer; third-line chemotherapy; prognostic factors |
| Author Name | Affiliation | E-mail | | Jingjing Liu | Jilin Provincial Cancer Hospital, Changchun 130012, China | jingjingstone@126.com | | Shuang Zhang | Jilin Provincial Cancer Hospital, Changchun 130012, China | zhangshuangphy@126.com | | Lixia Ma | Jilin Provincial Cancer Hospital, Changchun 130012, China | jl.cheng@163.com | | Chunjiao Wu | Jilin Provincial Cancer Hospital, Changchun 130012, China | jl.cheng@163.com | | Changliang Yang | Jilin Provincial Cancer Hospital, Changchun 130012, China | jl.cheng@163.com | | Xuerong Zuo | Jilin Provincial Cancer Hospital, Changchun 130012, China | jl.cheng@163.com | | Ying Cheng | Jilin Provincial Cancer Hospital, Changchun 130012, China | jl.cheng@163.com |
|
| Hits: 7103 |
| Download times: 8330 |
| Abstract: |
| Objective: As there is currently no clear recommendation for third-line chemotherapy for small cell lung cancer (SCLC), its efficacy is unknown. To date, there have rarely been reports of Chinese patients with
SCLC who received third-line chemotherapy. Therefore, we investigated the efficacy, safety, and prognostic factors of Chinese patients with SCLC treated with third-line chemotherapy.
Methods: A retrospective analysis of patients with SCLC who received third-line chemotherapy was performed.
Results: Between 2007 and 2013, 82 patients [62 men (75.6%), 20 women (24.4%); median age at the time of diagnosis, 55 years] received third-line chemotherapy at our center. Of these patients, 44 had limited-stage disease and 38 had extensive-stage disease. On third-line chemotherapy, 55 (67.1%) patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–1, objective response rate of 15.9%, and median overall survival after third-line chemotherapy (OS-3) and median progression-free survival after third-line chemotherapy (PFS-3) of 5.6 months and 3.0 months, respectively. On univariate analysis, PFS-3 was significantly related with ECOG PS (P = 0.005), response to second-line chemotherapy (P = 0.002), response to third-line chemotherapy (P < 0.001), and PFS after second-line chemotherapy (P = 0.026). OS-3 was significantly related with ECOG PS (P < 0.001), response to thirdline chemotherapy (P = 0.033), PFS after first-line therapy (P = 0.044), and PFS after second-line therapy (PFS-2) (P = 0.007). On multivariate analysis, ECOG PS (P = 0.008) and response to third-line chemotherapy (P = 0.046) were independent prognostic factors for PFS-3, while ECOG PS (P = 0.007) and PFS-2 (P < 0.001) were independent prognostic factors for OS-3.
Conclusion: Few patients with SCLC receive third-line chemotherapy. Our findings suggest that patients with an ECOG PS 0–1 and PFS-2 for >3 months will be benefit from third-line chemotherapy, which should be actively offered to them. |
| Close |
|
|
|